Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies
1998

Bone Morphogenetic Protein 6 in Skeletal Metastases from Prostate Cancer

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): P Autzen, CN Robson, A Bjartell, AJ Malcolm, ML Johnson, DE Neal, FC Hamdy

Primary Institution: University of Newcastle upon Tyne

Hypothesis

This study examines the expression of BMP-6 mRNA in matched prostatic primary and secondary bony lesions and in isolated skeletal metastases from prostatic adenocarcinomas, as well as other common human malignancies.

Conclusion

BMP-6 mRNA is strongly expressed in the majority of skeletal metastases from prostatic adenocarcinomas, suggesting it may be a potential marker and mediator of skeletal metastases.

Supporting Evidence

  • BMP-6 mRNA was detected in 11 out of 13 bone metastases from prostate carcinoma.
  • BMP-6 was also expressed in three paired samples of primary prostate carcinoma and matching skeletal metastasis.
  • Weak signals for BMP-6 were present in 5 out of 17 skeletal deposits from non-prostatic malignancies.

Takeaway

The study found that a protein called BMP-6 is often present in bone cancer from prostate tumors, which might help doctors understand and treat these cancers better.

Methodology

In situ hybridization was used to examine BMP-6 expression in matched primary and secondary prostatic adenocarcinomas and in isolated skeletal metastases.

Limitations

The study had a limited number of corresponding primary prostatic tumors.

Participant Demographics

Patients with established skeletal metastases from different primary cancers, including prostate, lung, kidney, breast, colon, and uterus.

Statistical Information

P-Value

0.0039

Statistical Significance

p=0.0039

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication